STEPS for Autism

Center for Youth Development and Intervention, Tuscaloosa, AL

Targeting 2 different conditionsSTEPSN/ARecruitingLed by Susan W WhiteResearch Sponsored by University of Alabama, Tuscaloosa

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Must not have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Upweek 14

Awards & highlights

No Placebo-Only Group

Study Summary

This trial will test an innovative program to help transition-age youth with ASD. It will involve stakeholders and be assessed for feasibility and impact.

Eligible Conditions

Autism
Autism Spectrum Disorder

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 14

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 14

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adult Functioning Scale

Rehabilitation Success

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: STEPSExperimental Treatment1 Intervention

All participants receive the STEPS intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

STEPS

2014

N/A

~270

Do I qualify?Apply below to find out

Find a site

Who is running the clinical trial?

University of Alabama, TuscaloosaLead Sponsor

37 Previous Clinical Trials

18,496 Total Patients Enrolled

Susan W WhitePrincipal Investigator

University of Alabama at Birmingham

Media Library

STEPS Clinical Trial Eligibility Overview. Trial Name: NCT05581069 — N/A

Autism Clinical Trial 2023: STEPS Highlights & Side Effects. Trial Name: NCT05581069 — N/A

STEPS 2023 Treatment Timeline for Medical Study. Trial Name: NCT05581069 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

For whom is this clinical trial an appropriate option?

"In order to be considered for this research, applicants must have a diagnosed autism spectrum disorder, be between the ages of 16 and 25 years old and have a caregiver willing to participate. Furthermore, they should also not currently be taking any medication that could affect their results."

Answered by AI

Is this exploration accepting enrollees at present?

"Clinicaltrials.gov reports that this medical trial is presently seeking to recruit patients, with the initial posting being on May 15th 2022 and latest edits made on October 11th 2022."

Answered by AI

Is this research study accepting participants aged 50 or above?

"This trial is available to patients aged 16-25 given that they meet all other eligibility requirements."

Answered by AI

How many subjects have enrolled in this clinical investigation?

"Affirmative. According to information available on clinicaltrials.gov, this study is currently recruiting individuals for participation. It was first published on May 15th 2022 and last modified October 11th of the same year. The single trial centre requires 25 subjects for enrollment."

Answered by AI